地诺单抗可能预防全髋关节和膝关节置换术后假体周围骨丢失：一项综述。
Denosumab might prevent periprosthetic bone loss after total hip and knee arthroplasties: a review.
作者信息
Xu Jianda, Li Huan, Qu Yuxing, Zheng Chong, Wang Bin, Shen Pengfei, Xie Zikang, Wei Kang, Wang Yan, Zhao Jianning
机构信息
Department of Orthopaedics, Changzhou Traditional Chinese Medical Hospital, Affiliated to Nanjing University of Traditional Chinese Medicine, 25 North Heping Road, Changzhou, 213000, Jiangsu, China.
Department of Arthroplasty, The First People's Hospital of Changzhou, Changzhou, 213003, China.
出版信息
Arthroplasty. 2021 Apr 12;3(1):13. doi: 10.1186/s42836-021-00068-6.
Total hip arthroplasty and total knee arthroplasty are extensively used for the treatment of the end-stage degenerative joint diseases. Currently, periprosthetic bone loss is still the major cause of aseptic loosening, resulting in implant failures. Previous literature introduced some widely accepted protocols for the prevention and treatment of periprosthetic bone loss, but no guideline has been proposed. Denosumab, a human monoclonal immunoglobulin G2 (IgG2) antibody, can inhibit bone resorption by binding to the receptor activator of nuclear factor kappa-B ligand (RANKL). This article reviews the present findings and evidence concerning the effect of denosumab on the periprosthetic bone loss after total hip arthroplasty and total knee arthroplasty. Overall, the current evidence suggests that denosumab is a promising agent for the treatment of periprosthetic bone loss.
全髋关节置换术和全膝关节置换术被广泛用于治疗终末期退行性关节疾病。目前，假体周围骨丢失仍然是无菌性松动的主要原因，导致植入物失败。先前的文献介绍了一些被广泛接受的预防和治疗假体周围骨丢失的方案，但尚未提出指南。地诺单抗是一种人源单克隆免疫球蛋白G2（IgG2）抗体，可通过与核因子κB受体活化因子配体（RANKL）结合来抑制骨吸收。本文综述了关于地诺单抗对全髋关节置换术和全膝关节置换术后假体周围骨丢失影响的现有研究结果和证据。总体而言，目前的证据表明地诺单抗是治疗假体周围骨丢失的一种有前景的药物。
Zotero 插件